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BORTEZOMIB AND HIGH-DOSEMELPHALAN AS A NOVEL CONDITIONING
REGIMEN FOR PATIENTS WITH POEMS SYNDROME UNDERGOING
AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
Tang, X., Shi, X., Hu, X., Xue, S., Qiu, H., Han, Y., Yan, L., Zhou, H.,
Liu, Y., Gu, B., Sun, A., Wu, D. Jiangsu Institute of Hematology,
Suzhou, Jiangsu, China
Background: POEMS syndrome is a multisystem disorder associ-
ated with plasma cell dyscrasias which characterized by polyneurop-
athy (P), organomegaly (O), endocrinopathy (E), serum M-protein
(M), and skin changes (S). Recently, we successfully treated two
POEMS syndrome patients by using bortezomib-based regimen
(VDD) and followed by autologous peripheral blood stem cell trans-
plantation (APBSCT) with bortezomib combined with high-dose
melphalan(Mel) conditioning regimen.
Methods: According to the latest Mayo Clinic criteria, two patients’
diagnosis of POEMS syndrome could be comfirmed. Both of them
had no response to the classical treatments, but achieved near com-
plete remission(CR) after 4 cycles and 1 cycle of VDD respectively
(Bortezomib 1.3-1.6 mg/m2/w4 weeks; 40 mg of Liposomal doxo-
rubicin on the fourth day of the first week; and 10 mg of dexameth-
asone during the initial 4 days of first cycle. Each course was at 21
days interval). Then, autologous peripheral blood stem cell collec-
tion was performed sucessfully (2.16106/kg and 3106/kg respec-
tively) after mobilization by cyclophosphamide (3g/m2/d for 1 day)
with subcutaneous G-CSF. APBSCT were performed approxi-
mately 1 month after stem cell collection. Two patients were
conditioned with Bortezomib 1.6mg/m2(d-13, d-6, d11, d17)1
Mel 200mg/ m2(d-3)and Bortezomib 1.3 mg/m2(d-8, d-1, d16,
d113)1Mel 200mg/ m2(d-2)respectively.
Results: No toxic death or serious adverse effects occurred during
APBSCT. Neutrophil and platelet recoveried at 110d, 127d and
17d, 120d respectively. Only case 1 patient developed mild hypox-
emia during neutrophil engraftment period, but was successfully
treated with corticosteroid and antibiotic therapy. The case 2 pre-
sented mucositis, diarrhea and nausea during neutropenic peroid.
A follow-up period were 14 and 8 months respectively. Both of
them achieved continuous CR. There was a dramatic improvement
in clinical symptoms and serum VEGF levels in all two patients
post VDD treatment including organomegaly (splenomegaly),
M-protein, pericardiac/pleural effusion,ascites and polyneuropathy.
Conclusion: This is the first report of POEMS patients treated by
APBSCT with bortezomib and high dose Melphalan conditioning
regimen. Our results suggest that Bortezomib is a new effective and
relative safe therapeutic option for POEMS syndrome not only in
the conventional treatment but also in APBSCT procedure.132
MULTIPLE MYELOMA PATIENTS OVER AGE 70 HAVE SIMILAR CLINICAL
AND COST OUTCOMES FOR AUTOLOGOUS TRANSPLANT COMPARED TO
YOUNGER PATIENTS
Pekurovsky, V., Cain, W., Bachier, C., LeMaistre, C.F.,
Shaughnessy, P.J. Texas Transplant Institute, San Antonio, TX
Randomized studies have shown that high dose melphalan and au-
tologous hematopoietic stem cell transplant (HSCT) can increase
disease free and overall survival for multiple myeloma (MM) patients
(pts) younger than age 65 years. Most patients with MM are diag-
nosed in their 7th decade and HSCT may be a viable treatment for
many of these pts. We performed a retrospective review at our insti-
tution of MM pts treated sequentially with melphalan and HSCT in
2009.Clinical outcomeswere reviewed for thewhole group, and clin-
ical and cost comparisonswere analyzed for pts age 70 and above, and
controls matched for sex, stage of disease, and number of prior ther-
apies.MediannationalCMS reimbursement rateswere used to estab-
lish costs of hospitalization and average sales price was used for costs
of medications. The cost analysis was limited to only significant vari-
ables for which data was available for both groups and does not rep-
resent the total cost of transplantation. Variables for the cost analysis
includeddose ofmelphalan, antibiotics,G-CSF, anddays of hospital-
ization. The dose of melphalan and the decision to hospitalize pa-
tients was based on the discretion of the attending physician.Results are summarized in the table.Therewas nodifferencebetween
the groups in the median number of CD341 cells infused or median
numberof doses ofG-CSF.Thenumber of co-existing diseases as de-
scribedon thepre-transplant essential data formswas similar between
the groups. No pts in the over age 70 group or the controls required
ICU level care. There was no transplant related mortality in the first
100 days for all patients.With a median follow up 9months, 49 of 51
pts survive (96%); one pt over age 70 died 6 months post transplant
from progressive disease and one pt under age 70 died 9 months
post transplant from progressive disease. Post transplant responses
in the pts age. 70 were CR 2/7 (29%), PR 3/7 (42%), and stable dis-
ease 2/7 (29%). Post transplant responses in the controlswereCR3/7
(43%) and PR 4/7 (57%). This study will be expanded to include pts
from prior years of transplant to expand the data base and length of
follow up, and to perform a more comprehensive cost analysis. In
conclusion, MM pts over age 70 treated with melphalan 140mg/M2
have similar clinical outcomes and costs of transplantation compared
to younger MM patients who undergo autologous HSCT.
Table 1. Results
Total N551 Age > 70 N57 Controls N57 pAge 60 (36-76) 73 (71-76)* 57 (51-69)* 0.0008Melphalan/M2 200 (140-200) 140 (140-200)* 200 (200-200)* 0.0005Hospital Days 9 (0-16) 11 (0-16) 5 (0-14) 0.11Day ANC > 500 11 (9-15) 12 (11-15) 12 (11-14) 0.24Costs NA $15K (6.4-22.7K) $13K (8.3-22.4K) 0.40Results are median and (range); K51000.
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PREDICTORS FOR ‘‘POOR MOBILIZERS’’ AFTER CYCLOPHOSPHAMIDE
MOBILIZATION IN MULTIPLE MYELOMA
Ozsan, G.H.1, Micallef, I.N.M.2, Dispenzieri, A.2, Kumar, S.2,
Lacy, M.Q.2, Dingli, D.2, Hayman, S.R.2, Buadi, F.K.2, Wolf, R.C.2,
Gastineau, D.A.2, Hogan,W.J.2, Gertz,M.A.2 1Dokuz Eylul University,
School of Medicine, Izmir, Turkey; 2Mayo Clinic, Rochester, MN
Autologous stem cell transplantation is an important part of
therapy in patients with the diagnosis of multiple myeloma. The
minimum number of CD34 positive cells required is 2x106 cells/
kg, but having more than 5x106/kg CD341 cells for transplantation
has several advantages. Some patients, fail to collect the minimum
number of cells and some patients require multiple aphereses to
reach the targeted dosage. To predict the outcome of mobilization,
several pre-mobilization predictive factors have been studied, but
still little is known about hematologic factors to predict outcome
of mobilization. The aim of this study is to determine predictive fac-
tors for outcome of stem cell mobilization in cyclophosphamide 1
growth factor mobilized (CY-Mob) patients.We evaluated the white
blood cell count (WBC), platelet (Plt) and CD34 1 cell kinetics in
CY-Mob patients. 396 consecutive CY-Mob attempts between Jan-
uary 2000 - December 2009 in Mayo Clinic, Rochester, MN were
analyzed. Patients were divided into two groups; good mobilizer
(. 2x106/kg CD341 cells) or poor mobilizer (\ 2x106/kg CD341
cells). The good mobilizer group was further divided into optimal
(. 5x106 CD34/kg) and suboptimal (2-5x106 CD34/kg) groups.
The optimal group was further divided into two groups based on
the number of required apheresis. In the poor group pre-mobiliza-
tion Hb, WBC and Plt counts were statistically significantly lower
than good mobilizer group. Time from ‘‘WBC . 1 to peripheral
CD341cells . 10/uL’’ was statistically significantly less in the
good mobilizer group (0 vs. 2 days p 5 0.0005) (table1). When we
compared the optimal and suboptimal groups, days needed to have
‘‘CD341cells. 10’’ and ‘‘WBC. 1 to CD341cells. 10’’ were sig-
nificantly fewer in optimal group (p5 0.0001). In the optimal group,
which required # 3 apheresis, the median day for ‘‘CD341cells .
10’’, was 11 and 90% of the patients reached this goal within 14
days. In ROC analysis the cut-off point was found to be day 13.
Days spent to reach ‘‘peripheral blood CD341cells . 10’’ and
‘‘WBC. 1 toCD341 cells. 10 ‘‘ were found to be useful predictive
Table 1.
Age
Nadir
wbc Nadir plt
Days to
wbc>1
Days to CD34>10,
median (quartiles)
Days between
wbc>1 to 34>10,
median (quartiles)
Good (n5370) 58 0.3 68 11 12 (11-13) 0 (0-1)
Poor (n526) 64 0.2 30 12 13 (13-16) 2 (2-3.5)
P value 0.003 0.07 0.02 0.03 0.01 0.0005
Optimal (n5340) 58 0.3 67 11 12 (11-13) 0 (0-1)
Suboptimal (n530) 65 0.3 83 12 14 (11.75-15) 1.5 (0.75-2)
P Value >0.05 0.3 0.5 0.1 0.0001 0.0001
Optimal <3apheresis (n5307) 58 0.3 67 11 11 (11-13) 0 (0-0)
Optimal >3 apheresis (n533) 59 0.4 80 12 14 (12-16.75) 2 (0-3.75)
P Value >0.05 0.2 0.9 0.2 0.0001 0.0001
Good: CD34+cells>2x106/kg, Poor: CD 34+ cells <2x106/kg, Optimal: CD34+cells >5x106/kg, Suboptimal: CD34+cells: 2-5x106/kg
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geted for transplantation (. 5x106/kg), the delay in the days to
CD341 cells. 10 in peripheral blood can be considered to be a rea-
son formodifying themobilization regimen, like adding plerixafor. If
the CD34 count is still\ 10 one day after the day WBC . 1.0, ad-
dition of plerixafor to the mobilization regimen should be strongly
considered.134
AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
IN THE ERA OF NOVEL AGENTS: IMPACT OF DEPTH OF RESPONSE TO IN-
DUCTION THERAPY. A SINGLE INSTITUTION EXPERIENCE
Tapia, M.G.1, Olarte, K.2, Mckinnon, R.1, Ruemenapp, K.1,
Janakiraman, N.1 1Henry Ford Hospital, Detroit, MI; 2Henry Ford Hos-
pital, Detroit, MI
Background: High-dose chemotherapy and autologous stem cell
transplantation (ASCT) in newly diagnosed multiple myeloma is
the standard of care for eligible patients. Prior to ASCT, induction
therapy is administered for 1 to 4 months before stem cell collection.
Eligible patients undergo ASCT regardless of the response to induc-
tion therapy because it has been shown that a good response is not
essential in order to obtain survival benefit from ASCT. A recent
study that evaluated the novel agents, thalidomide and lenalidomide
demonstrated that failure to achieve a partial response after induc-
tion therapy predicts a poorer outcome after ASCT.
Methods: Fifty patients (60% male; median age 59 years) with mul-
tiple myeloma who underwent high-dose chemotherapy and ASCT
after induction therapy with thalidomide, lenalidomide or bortezo-
mib were retrospectively studied. The patients were divided into
two groups according to their response after induction therapy:
those with CR or VGPR; and those with PR or less than PR. Statis-
tical analyses were performed.
Results:The median follow up was 33.4 (2.9-71.2) months. TheM-
protein at diagnosis was 3.46 1.7 g/dl and the stage (Durie-Salmon)
of the multiple myeloma was IIIa in 33 (66%) and IIIb in 9 (18%) pa-
tients. Beta-2 microglobulin was 4.96 4.7 g/ml and 40% of patients
had unfavorable cytogenetics defined as 13q- by cytogenetics, t
(4,14), t(14,16), 17p- and complex karyotype. Favorable cytogenetics
included normal, t(11,14) or 13q- by FISH. The induction therapy
was thalidomide in 23 (46%), lenalidomide in 9 (18%), bortezomib
in 8 (16%) and a combination in 10 (20%). The patients who
achievedCR orVGPR after induction therapywere 23 (46%). These
responses were associated with longer time to progression (HR 5
0.42; p5 0.055) after ASTC.The progression-free survival (PFS) es-
timates for CR or VGPR vs PR or\PR were 48.6 months and 21.5
months respectively (p 5 0.013). The presence of favorable cytoge-
netics was associated with a longer time to progression (HR5 0.345;
p5 0.0174). A higher beta-2 microglobulin was associated with ear-
lier time to progression (HR 5 1.073; p 5 0.0272).
Conclusion: Achieving CR or VGPR with the novel agents prior to
ASCT predicts a better PFS after transplantation. This suggests thatextending induction therapy to achieve CR or VGPR prior to ASCT
might be beneficial. Larger studies are needed to confim this finding.135
CARDIOMYOPATHY FOLLOWING HIGH DOSE MELPHALAN CONDITION-
ING PRIOR TO AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANS-
PLANTATION FOR MULTIPLE MYELOMA AND PRIMARY AMYLOIDOSIS
Bleeker, J.S.1, Gertz, M.A.1, Pellikka, P.A.2, Buadi, F.1, Dingli, D.1,
Dispenzieri, A.1, Hayman, S.R.1, Hogan, W.1, Kumar, S.1,
Lacy, M.Q.1 1Mayo Clinic, Rochester, MN; 2Mayo Clinic, Rochester, MN
Background: High dose melphalan (HDM) is a commonly utilized
conditioning regimen prior to autologous peripheral blood stem cell
transplantation (PBSCT) for multiple myeloma and primary amy-
loidosis. Although cardiotoxicity from this regimen has not been de-
scribed, there are multiple anecdotal cases of transient
cardiomyopathy following HDM in the Mayo Clinic transplant ex-
perience. Thus, we reviewed our experience to determine the fre-
quency of cardiomyopathy in this setting.
Methods: From our database of all patients undergoing autologous
PBSCT for myeloma or amyloidosis from 1989-2009, we identified
those with echocardiograms performed before and within 4 months
of PBSCT, and reviewed these for evidence of cardiomyopathy, de-
fined as a decrease in left ventricular ejection fraction (LVEF) of $
10% to a value of # 50%. Charts of patients meeting these criteria
were reviewed to determine conditioning regimen, pre-existing car-
diac risk factors and other potential causes of cardiomyopathy to de-
termine the association between the cardiomyopathy and HDM.
Results:Of 1476 patients (1050 myeloma; 426 amyloidosis) who re-
ceived HDM as a component of conditioning prior to PBSCT, 407
had echocardiography before and within 4months after PBSCT, and
40 (2.7%) met criteria for cardiomyopathy. When accounting for
other risk factors, HDMwas felt to be a probable cause of cardiomy-
opathy in 16 patients, a possible cause in 18, and an unlikely cause in
6. Cardiomyopathy was noted more frequently in patients undergo-
ing PBSCT for amyloidosis (23/426, 5.4%) than myeloma (17/1050,
1.6%). All 23 patients with amyloidosis received HDM alone as con-
ditioning (dose range 140-200 mg/m2). Fifteen of the 17 myeloma
patients received HDM alone as conditioning (dose range 140-200
mg/m2), with two patients receiving HDM in concert with total
body irradiation and ibritumomab, respectively.
The mean pre-PBSCT LVEF in this cohort was 59% (range 42-
70%), which decreased to a mean of 38% (range 15-50%) following
PBSCT. Diagnosis of cardiomyopathy was made within 30 days of
PBSCT in 65% (26/40) of patients. Follow up echocardiography
was performed in 26 patients, with 15 showing improvement in
LVEF to $ 50%.
Conclusion: To our knowledge, this is the first series to report car-
diomyopathy following HDM conditioning. Further work should
focus on identifying pre-transplant variables which may predispose
patients to cardiotoxicity following conditioning with HDM.
